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Histamin und Stressulcus: Neue Strukturen 
in der Darstellung einer Sequentialstudie 
fiber Cimetidinprophylaxe bei Schwerkranken 
und Definition einer speziellen Risikogruppe 
Zusammenfassung. Bei Patienten der chirurgischen 
Wach- und Intensivstation wurde eine kontrollierte 
klinische Studie fiber den Wert yon Cimetidin zur 
Strel3ulcusprophylaxe durchgeffihrt. Die fibliche Or- 
ganisation und Darstellung einer kontrollierten Studie 
muBte wegen erheblicher theoretischer, ethischer und 
praktischer Schwierigkeiten bei Planung und Durch- 
ffihrung ge~indert werden: 
(1) Zuerst wurde die Untersuchung bei Patienten 
der Wach- und Intensivstation als randomisierte Dop- 
pelblindstudie mit fixem Stichprobenumfang geplant. 
Ausgeffihrt wurde eine einfach-blinde Sequentialstu- 
die ausschlieBlich bei Patienten mit schwerem Poly- 
trauma. Kurz vor Erreichen der vorgegebenen Signifi- 
kanzgrenzen wurde sie aus ethischen Grfinden abge- 
brochen und nach Beratung mit einem externen Gut- 
achter mit Hilfe des exakten Testes nach Fisher analy- 
siert (p < 0,025). 
(2) Die notwendigen I formationen fiber die Stu- 
die konnten nicht in einem einzigen Bericht zusam- 
mengeprel3t werden. Als einer der Teile enth/ilt diese 
Mitteilung Plan, Klinisches Material, Methoden und 
Statistik der Studie. Abschnitte fiber ,,Theoretische 
und ethische Aspekte" und fiber ,,Historische Ent- 
wicklung der Studie" wurden eingeffigt. Zahlreiche 
Entscheidungen wurden bereits in Material und Me- 
thodik erlfiutert, um die enorme Komplexitfit des Ent- 
scheidungsprozesses b i klinischen Studien im Gegen- 
satz zu der bei Tierexperimenten hervorzuheben. 
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(3) Um Schl/isse yon der Stichprobe auf die Ziel- 
population zu erleichtern u d Risikogruppen ffir StreB- 
ulkusentstehung zu definieren, wurden alle 6,634 Pa- 
tienten der Klinik w/ihrend der Dauer der Studie pro- 
spektiv auf klinisch-manifeste StreBlfisionen unter- 
sucht. Als eines der wichtigsten Merkmale wurde wei- 
terhin die Letalit/itsrate fiir die Gesamtgruppe und 
f/Jr Untergruppen der Traumapatienten i  unserer 
Klinik ermittelt. 
StreBulcera traten nur bei Patienten der Wach- 
und Intensivstation auf, vor allem bei Patienten mit 
schwerem Polytrauma und postoperativen Komplika- 
tionen. Cimetidin verhfitete sic fiuBerst wirksam beim 
schwer Polytraumatisierten. Es ist aber unn6tig, das 
Arzneimittel fiber die Wach- und Intensivstation aus- 
zustreuen wie aus einem Ffillhorn des Gliicks. 
Sehliisselwiirter: StreBulcus Arztliche Ethik - Se- 
quentialstudie - Cimetidin - Schweres Polytrauma 
Summary. In patients in a surgical intensive care unit 
a controlled clinical trial was performed concerned 
with the pathophysiological functions of histamine 
in stress ulcer disease and with the influence of cimeti- 
dine prophylaxis on this complication. The commonly 
used organization of a controlled clinical trial was 
enforced to be changed by considerable theoretical, 
ethical and practical difficulties in designing and con- 
ducting the study: 
(1) Initially the trial was planned as randomized 
double-blind using a fixed sample size of patients 
obtained from the intensive care unit. It was executed 
as a sequential single-blind study only in patients with 
severe polytrauma. For ethical reasons it was stopped 
before the bounderies were reached and was analysed 
according to the advice of an external referee using 
Fisher's exact test (p < 0.025). 
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(2) The necessary informations about the trial 
could not be compressed to one single report. As 
one of several parts this article mainly deals with 
Design, Clinical materials, Methods and Statistics of 
the whole investigation. Distinctive sections on Theo- 
retical and Ethical issues and on Historical develop- 
ment of the study were included. Numerous decisions 
were explained already in Materials and Methods to 
emphasize the enormous complexity of the decision 
process in clinical trials in contrast o that in most 
of the animal experiments. 
(3) In order to facilitate conclusions from our 
sample to the target population and to define sub- 
groups of patients with a high risk for stress ulceration 
all 6,634 patients hospitalized in the Surgery Clinic 
during the time of the study were prospectively inves- 
tigated for clinically manifest stress ulceration. Fur- 
thermore as one of the most important attributes the 
lethality rate was calculated for the whole group and 
various subgroups of trauma patients in our hospital. 
As a surprising and remarkable result of the study 
clinically manifest stress ulcers occurred exclusively 
in our patients in the intensive care unit and among 
them mainly in those with severy polytrauma and 
postoperative complications. Cimetidine was highly 
effective in preventing stress ulceration in severe poly- 
trauma patients. But it seems absolutely unnecessary 
to distribute this drug in all patients of a surgical 
intensive care unit like from a cornucopia of happiness. 
Key words: Stress ulceration Medical ethics - Se- 
quential trial - Cimetidine - Severe polytrauma 
The therapeutic benefit of the H2-receptor antagonist 
cimetidine in chronic duodenal ulcer disease has been 
established through more than numerous controlled 
clinical trials [15, 18, 33, 46, 71]. In the prophylaxis 
and treatment of acute gastroduodenal lesions, how- 
ever, the advantages of cimetidine have only been 
suggested by the results of animal experiments [14, 
86, I00], clinical case reports [6, 24, 75, 94], retrospec- 
tive trials and prospective trials using either historical 
controls [13, 52, 82, 107] or patients from highly 
selected groups [25, 26, 30, 42, 76, 112]. Since hista- 
mine H2-receptors in acid secretion [9] and microcir- 
culation [41] and histamine release from intra- and 
extragastric cellular stores [64, 65, 105, 106] are likely 
to play an important role in the pathogenesis of acute 
as well as chronic gastroduodenal ulceration it could 
be expected that therapy using H2-receptor antago- 
nism could offer clinical advantages to patients likely 
to or developing stress ulcerations. 
To test this hypothesis in the clinical setting a 
controlled trial concerned with the pathophysiological 
functions of histamine in stress ulcer disease and with 
the influence of cimetidine prophylaxis on this com- 
plications was conceived and conducted. The plan- 
ning of the study started with the large group of 
seriously-ill patients in a surgical intensive care unit. 
Its execution ended up in only the subgroup of pa- 
tients with severe polytrauma. 
From this statement i becomes clear that during 
the time of investigation we were confronted with 
so many surprising events and findings that the neces- 
sary informations about the trial could not be 
compressed to one single original report. As one of 
probably four communications this article especially 
comprises three aims: (1) Design, Clinical materials 
and Methods of the trial were described as carefully 
as possible. (2) New components in organizing perfor- 
mance and presentation of a clinical trial had to be 
introduced. These include mainly the distinctive sec- 
tions on Theoretical and Ethical issues and on Histor- 
ical development of the study. However, it was also 
necessary to explain the numerous decisions to be 
made in planning and conducting the study imme- 
diately in the section of Materials and Methods and 
not as usually demanded - in Discussion. Such 
deviations from the common organization of a scien- 
tific paper were necessary to emphasize the complex- 
ity of the decision process in clinical trials. (3) Sub- 
groups of patients with a high risk for stress ulceration 
were defined especially those with severe polytrauma. 
Only this group of critically ill patients ended up 
in the trial on cimetidine prophylaxis. To acchieve 
the third aim all 6,634 patients hospitalized in the 
Surgery Clinic during the time of the trial were pro- 
spectively investigated for clinically manifest stress ul- 
ceration. 
Materials and Methods 
1. Theoretical and Ethical Issues 
In conceiving the controlled clinical trial on the effects of therapy 
with cimetidine on the development and outcome of acute gastro- 
duodenal lesions we met considerable difficulties: 
(1) In patients of a surgical intensive care unit many patholog- 
ical states and stressful conditions could be identified which probably 
were associated with a high risk of acute gastrointestinal ulceration 
(Table 1). Unfortunately this argument could be validated only 
by findings from animal experiments, numerous, but retrospective 
and uncontrolled surveys and a few prospective trials without con- 
trol groups or without reliable determination f a risk rate. Just 
to convince ourselves and to form a theoretical data base for 
our designing the most reliable xperimental and clinical studies 
to our knowledge and opinion were compiled in Table 1. In all 
the conditions mentioned, however, by no means the pathogenesis 
of stress-induced l sions could be considered asidentical or uniform 
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Table 1. Pathological states and stressful conditions associated with acute gastroduodenai lesions 
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Condition Hypothesis tested by 
Report or review on 
animal experiments 
Prospective trial or 
reliable clinical survey 
Trauma Friesen et al. [35] 





Merendino et aI. [79] 
Cushing [19] 
Menguy et al. [78] 
Mullane et al. [81] 
Fat embolism Baronofsky and Wangensteen [5] 
Renal insufficiency Mullane et al. [80] 
Infection (sepsis) Rasche and Butterfield [85] 
Mc Cracken et aI. [74] 
Immobilization Bonfils et al. [10] 
Psychological stress Par6 [83], Sawrey et al. [95] 
Burns Hartman [45] 
"Ulcerogenic'" drugs Robert and Nezamis [89] 
Di Pasquale [23] 
Bowen and Fleming [11] 
Glass and Stremple [37] 
Weber et al. [111] 
Kamada et al. [53] 
Goodman and Frey [38] 
Skillman et aI. [101] 
Harris et aI. [44] 
Mears [77] 
Fischer and Stremple [29] 
Le Gall et al. [58] 
Lucas et al. [70] 
Holle [48] 
Wolf and Wolff [113] 
Czaja et al. [20] 
Feller [28] 
Kapp et al. [55], Welch et al. [112} 
Rainford [84], Roth [93] 
[17, 19, 56, 59, 77, 84, 93, I02]. Depending on their combination 
cimetidine could be effective and harmless in the one patient, but 
ineffective and harmful in the other. Stratification or a study on 
several distinct subgroups of patients was considered, but the condi- 
tions in Table 1 unfortunately were mixed up in the critically 
ill patients in a highly irregular way. In addition, for their prevention 
and treatment about a dozen of drugs was administered to a single 
patient per day complicating the evaluation of the effects of cimeti- 
dine considerably. 
(2) Varying time relationships between the numerous conditions 
in table 1 diminished the precision of the criteria for a patient 
entering the trial to a critical extent [22]. If for instance" respiratory 
insufficiency" was the attribute of selection the one patient just 
had acquired it by a thorax trauma in a car accident, the other 
by suffering from fat embolism 2 4 days after the accident, the 
other by septical complications 10-20 days after the accident. This 
was one of the reasons why a trial on stress ulcer prophylaxis 
by cimetidine could be standardized a little easier than that on 
treatment [30]. 
(3) Few and incomplete attempts were found in the literature 
[4, 54] to grade the severity and intensity of the pathological states 
and stressful conditions (Table 1) with respect to their risk for 
stress ulceration. It was for instance impossible to decide whether 
all patients with trauma should obtain cimetidine prophylaxis, or 
only those with potytrauma or exclusively those with severe poly- 
trauma. This problem would have been of rather minor interest 
if surgical and severely ill patients would not also be exposed 
to special risks other than stress ulceration. These could be in- 
fluenced by cimetidine. For instance, alterations were found within 
their immune system [109] which in duodenal ulcer patients very 
probably is not impaired by cimetidine [57]. But histamine Hz- 
receptors have been demonstrated in various immunological test 
systems [108] and it is far from clear which role histamine plays 
in various life-preserving defense mechanisms of severely ill pa- 
tients. Furthermore, cerebral disturbances and renal failure which 
promote stress ulcer formation (Table 1) occur quite regularly 
in these patients, but may also be elicited by cimetidine [96]. Thus 
it is by no means justified to distribute the drug to all patients 
of intensive care units, but only to those who are really at risk 
for acute ulceration. 
(4) Since only surgical and critically ill patients were selected 
for our trial particular ethical problems arose which opposed a 
more rigid "scientific" approach [68], Routine fiberoptic endo- 
scopy for instance was regarded as a safe procedure in patients 
with uncomplicated gastroduodenal u cer disease [92], but not in 
polytraumatized patients uffering from serial costal fractures, seri- 
ous tung injury, tracheotomy - all these local obstacles associated 
with shock, hepatic and renal insufficiency and septicat complica- 
tions. For this reason the local ethical committee did not permit 
us diagnostic endoscopy in any of the patients admitted to trial 
before clinically manifest gastrointestinal bleeding occurred. Other 
ethical conflicts will be discussed in the following section. 
All these difficulties prompted us to do our best in skilfully 
designing the trial, but also to alter the plan and conduct of the 
study at various steps of the performance. 
2. Historical Development of the Trial 
February 1976: Continuing previous tudies on histamine and stress 
ulcers [59, 61] the first setting of a double-blind randomized 
controlled trial was produced on cimetidine prophylaxis in patients 
of the intensive care unit. 
100 patients considered at risk (Table 1, [92]) for clinically 
manifest ulceration (incidence about 20 per cent) should enter the 
trial running for about 1824 months. Six major indications were 
included [59]: severe burns, severe cerebral injury, severe poly- 
trauma, postoperative complications, major surgery and respira- 
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Table 2. Definition of severe polytrauma. (For further comments 
and conditions ee text in Sect. 2.3) 
Injury with danger to life and possible physical disability 
At least 3 body regions affected 
a) 3 body cavities (head, thorax, abdomen) 
b) 2 body cavities+ 1 extremity fracture 
c) 1 body cavity+2 extremity fractures 
d) 3 extremity fractures 
Body cavity= lesions within the body cavity or on its walls 
Extremity fracture = fracture of a long bone (humerus, radius, ulna; 
femur, tibia, fibula) 
tory insufficiency, Patients with bleeding abnormalities, history 
of peptic ulcer, gastric arcinoma, oesophagus and lung resections 
(problems with endoscopy !) were put in escape. 
The regimen of drug administration (cimetidine and placebo) 
was defined as described inMethods. The randomization list should 
be performed by the company Smith, Kline and French (SKF) 
and sets with drug or placebo medication should be delivered 
to the clinicians by SKF to allow a double-blind esign. 
The following attributes and parameters were selected and 
defined: (1) Gastroduodenal ulcerations in patients admitted to trial 
should be recorded both as clinically manifest and non-clinical 
lesions. The first ones should be assessed at any time during the 
treatment period and the rest of hospital stay using emergency 
endoscopy and - if necessary - X-rays. The second ones should 
be detected with the aid of two diagnostic endoscopies 5 and 14 
days after admission to trial. In the escape group and in all other 
patients hospitalized during the trial period only clinically manifest 
lesions hould be noted. (2) As criteria for the final outcome death 
or survival should be recorded. (3) Onset and duration of patholog- 
ical states and stressful conditions (Table 1) should be assessed 
by standard clinical findings and laboratory tests. (4) The standard 
programm of clinical-chemical tests for studying new drugs [21] 
should be applied to the patients in trial and in the escape group. 
Additionally histamine in plasma and in mucosal biopsies hould 
be determined during the treatment period. 
July 1976. Resulting from various meetings the decisions about 
setecting patients for trial, escape and drop-out were changed and 
definitely specified (see Table 3 and 4). Instead of 6 only 4 sub- 
groups of severely ill patients were included. In view of the results 
presented later on in this communication unfortunately the sub- 
group of "postoperative complications" was eliminated, but the 
onset of this pathological state (Table 1) was considered as often 
too vague to allow a precise start with drug application. The sub M 
group of "major surgery" was eliminated since already from retro- 
spective analysis the incidence of stress ulceration was found to 
be low in the patients of our clinic. The remaining 4 subgroups 
were conclusively defined: (1) Severe burns=at least 25% of the 
body surface and 2nd degree (2) severe cerebral injury=uncon- 
sciousness for at least 72 hours, (3) severe polytrauma=at least 
3 body regions, (4) respiratory insufficiency =controlled respiration 
for at least 8 hours [30], From retrospective analysis of 3 yearbooks 
of the intensive care unit we expected about 20, 20, 40 and 40 
patients respectively in the 4 subgroups within 18 24 months (total 
number 120) [301. 
December 1976. The definite protocols were submitted to the local 
ethical committee (SFB 122 of Deutsche Forschungsgemeinschaff) 
chaired by H. Hensel [47]. For ethical reasons [3] they were enforced 
to be altered in two important components: (1) A sequential study 
Table 3. Escape from trial for patients with severe polytrauma. 
(For further comments and conditions ee text in section 2.3) 
Informed consent was obtained not only by the patients, but also 
by their relatives because of the critical situation of their admission 
Death before first treatment 
Admission to hospital, recognition as candidate for trial, or treat- 
ment by cimetidine more than the next day after the incident 
No consent to enter the trial 
Age less than 18 years 
History or clinical evidence of either duodenal or gastric ulcer, 
atrophic gastritis or gastric arcinoma 
History of gastric operations (increased reflux) (93) 
Primary bleeding abnormalities 
Severe renal or liver insufficiency, or bone marrow disease (decision 
of the executive group) 
Table 4. Drop-out from trial for patients with severe polytrauma. 
(For further comments and conditions ee text in section 2.3) 
Stress ulcerations following prophylaxis by placebo 
Unreliable drug intake or recede from trial 
Failures in treatment pertinent to trial (decision of the executive 
group) 
Transfer to other hospitals within the 2 weeks of prophylaxis 
Development of severe renal or liver failure or leucopenia or other 
signs of bone-marrow damage (decision of the executive group) 
Significant reactions reasonable attributable to the drug (decision 
of the executive group) 
was preferred since cimetidine being provided for usually life- 
threatening conditions was already theoretically favoured for stress 
ulcer prophylaxis [76]. The new design had to be worked out sepa- 
rately for the 4 subgroups and the trial was not longer accepted 
as donNe-blind, but only as single-blind (at least for the academic 
staff). For this reason, however, a patient not longer could be 
excluded from trial by decision of a single physician, but only 
by that of an executive group. (2) Diagnostic endoscopy was no 
longer accepted though this procedure was used in several trials 
in USA [11, 20] and Japan [53]. A harmful effect of endoscopy 
could not be excluded in the severely-ill patients, especially those 
with severe polytrauma. Thus only clinically manifest stress ulcer- 
ations were selected as the decisive criterion for success or failure 
of cimetidine prophylaxis and no biopsies could be taken for hista- 
mine assays. The finding that no correlation existed between the 
rates of clinically manifest and non-clinical stress ulcerations [t1] 
was helpful to us to accept his restriction of our trial. 
February 1977. The staff of the clinic and especially of the intensive 
care unit was informed and motivated before the start of the trial. 
In three sessions of our weekly seminar for training in surgical 
research [63] questions, design, methods, risks and ethical problems 
of the trial were discussed with all clinicians and basic research 
scientists in the Department who finally agreed, tn two additional 
meetings the nurses and technicians of the intensive care unit and 
the anesthesiologists were informed and convinced in the same 
way. 
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For the trial period an executive group was defined consisting 
of 6 clinical and 2 theoretical surgeons [63]. It included the 2 
academic members of the small working group for stress ulcer 
[63], the chairmen of the 2 Units, 2 consultants and 2 senior regis- 
trars. To reduce observer variation [43] all members of the group 
had been trained in systematic follow-up [91] and endoscopy during 
a 3-year prospective trial [92]. The clinical surgeon of the small 
working group tbr stress ulcer, M.F., and in his absence the chair- 
man of the prospective study on endoscopy [92], H.R., had to 
admit the patients to trial in all "c lear" cases. In all questionable 
cases, however, including those for escape or drop-out at least 
3 members of the executive group had to agree. Except the chief- 
surgeon all 5 clinical surgeons were responsible for a 24-hour endo- 
scopy service including weekends, holidays etc. After their training 
they agreed to the same definitions for lesions and bleeding activity 
but even in night-duty at least two of them had to record and 
describe the lesions. Blood for plasma histamine assay was taken 
only by M.F. and in his absence by one of the senior registrars 
K.H.V., who were especially trained to prepare the plasma under 
optimum conditions [62]. 
March 1977. The execution of the trial started on March 15. Be- 
cause of the expectedly high lethality rate the team met every 
fortnight to decide whether the trial should be continued or 
stopped. Furthermore, the staff of the clinic was informed and 
motivated again and again in our weekly seminar for training 
in surgical research [63]. 
Despite atI this efforts important events and failures happened 
in the period of execution which strongly influenced the course 
of the trial and finally resulted in exclusion of atl but one sub- 
groups. 
(1) In May 1977 the consultant specialized for burns left the 
clinic. Many patients with burns, especially those with the more 
severe lesions, were lost by a shift in hospital admission from 
Marburg to Giessen. This led to exclusion of subgroup l from 
trial in October 1977 for practical reasons. 
(2) In September 1977 a failure in the trial design was detected 
in subgroup 2. About one week after hospital admission patients 
with severe head injury as single trauma (Table 6) were transferred 
to the neurological clinic (drop-out condition 4, Table 4). Those 
with polytrauma (not severe polytrauma!) remained in subgroup 
2. In January 1978 a neurosurgical unit was opened in our clinic. 
Also patients with severe head injury as single trauma were kept 
now more or less in our intensive care unit (with some adaptation 
effect !) and more sophisticated surgery was performed in them, 
Thus in February 1978 subgroup 2 was excluded from trial because 
of selection bias, critical inhomogenity in combination with a small 
number of patients, 
(3) In March 1978 subgroup 4 had to be excluded from trial 
a most regretable decision since already 26 patients had entered 
the study. However, in executing the trial we became more and 
more aware of the strongly variable time relationships between 
respiratory insufficiency and the other pathological states in Table 
1 (see theoretical issues). Indeed, the imprecise ntrance criteria 
became apparent by practical difficulties which finally led to the 
exclusion of the subgroup. Whereas the admissions of patients 
with severe polytrauma were such dramatic events that they were 
easily recognized even after one year of trial persistence with all 
its fading effects two patients with controlled respiration for 12 h 
were simply overlooked uring a weekend. The anaesthesiologist 
in duty forgot to announce them, the surgeon of the executive 
group did not ask rigorously enough. Being sensitized we became 
aware of similar faults in the past and again suspected a selection 
bias which led to the exclusion of the subgroup. 
All three subgroups excluded from the trial with cimetidine 
prophylaxis were followed-up among all the other patients admitted 
Table 5. Clinically manifest stress ulcerations in all patients of 
the surgery clinic - a prospective study. All patients with stress 
ulcerations developped the lesions within the clinic, none of them 
was included who was admitted or readmitted to hospital for this 
indication. Time of the trial March 1977 June 1978. Incidence in % 
(95% confidence limits) (two-sided) or 97.5% (one-sided) 
* 0.0 (0 0.07)% for all patients being not in the intensive care 
unit 
Patients Lesions 
Ward Indication Number Number Incidence 
(nO (n2) (nz/n0 [%] 
Intensive Trauma 232 7 3.0 
care unit Others 848 t3 1.5 
Total 1,080 20 1.9 
(1.16-2.82) 
Casualty Single trauma 701 0 0.0 
Polytrauma, 111 0 0.0 
> lSys  
Polytrauma, 13 0 0.0 
14-18 ys 
Total 825 0 0.0 
Children's Single trauma 228 0 0.0 
(< 14 ys) Polytrauma 23 0 0.0 
Total 251 0 0.0 
Other wards Total 4,478 0 0.0 * 
and parts of 
the wards 
All hospital Total 6,634 20 0.3 
admissions 
to our clinic concerning stress ulceration (Table 5, 6) and lethality 
rate (Table 7). 
June I978. Even for the only remaining subgroup of patients with 
severe potytrauma the trial was stoppedJbr ethical reasons before 
the bounderies of the sequential plan were reached. On June 15 
when already 28 of these patients had entered the trial the fifth 
patient in the placebo group started with bleeding from gastric 
erosions compared to none in the cimetidine group (see also Table 
6). After 8 h the bleeding stopped following therapeutic application 
of cimetidine, but the patient died at the same day from circulatory 
insufficiency. Since in the placebo group already two 18 years 
old patients had died after massive haemorrhagic gastritis under 
dramatic ircumstances all members of the executive group agreed 
to stop the trial. As an external referee we asked H. Immieh, 
Heidelberg, who confirmed our decision. According to his advice 
we used the exact test of Fisher (one-sided) [32] for only once 
testing the null hypothesis and obtained a probability value of 
p<0.025. Thus cimetidine apparently was highly effective in pre- 
venting stress ulceration in patients with severe polytrauma. 
3. Methods and Definitions in the Trial Restricted 
to Severe Potytrauma 
Severe Polytrauma. Two pathophysiological findings had to be 
considered to find a clinically simple and sufficiently reliable defini- 
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Table 6. Clinically manifest stress ulcerations in patients of the 
intensive care unit from which the patients with severe polytrauma 
were selected for trial. Patients were admitted to the intensive 
care unit when their condition was considered life-threatening and 
additionally in some cases unknown of origin. There were few 
exceptions which were specified separately. In all cases of stress 
ulceration reacerbation of a chronic ulcer was excluded by case 
history, clinical findings and microscopical examination. - Defini- 
tion of the classes: Single trauma = trauma of life-threatening sever- 
ity, with complications such as fat embolism (see also [99]), singular 
cerebral injury (68 cases), blunt abdominal trauma (22 cases), gun- 
shot injury, stab wound and burns. - Polytrauma was defined 
with the same terms as severe polytrauma (Table 2), but was only 
restricted to 2 lesions. - Acute abdomen=ileus, gastro-intestinal 
bleeding, biliary diseases, pancreatitis etc. -- Postoperative complica- 
tions= wound ruptures and leakages etc. including all further conse- 
quences uch as peritonitis, renal and respiratory insufficiency etc. 
Patients at risk defined according to Wawersik et al. [110], i.e. 
with preoperative risks, such as age, lung emphysema etc., but 
not with trauma or acute abdomen. Major surgery =total gastrec- 
tomy, Whipple's operation, lung resection etc., but without signifi- 
cant postoperative complications. Respiratory and cardiac insufj~- 
ciency=patients with these primary diseases not operated upon 
or developping them in later, usually uncritical phases of tile recon- 
valescence after operation, such as after myocardial ischaemia. 
- Severe infections =tetanus and sepsis after minor injuries. - Other 
sporadic indications=endocrine disturbances (4 cases), suicidal in- 
tents with drugs (4 cases), shortage in beds (11 cases) and patients 
with no definite final diagnoses (73 cases). - The subgroup of 
26 patients with respiratory insufficiency admitted to trial (14 
treated with cimetidine, 12 with placebo) was included in the classes 
o f "  postoperative complications" and "respiratory insufficiency". 
Since both a patient with postoperative complication (P.C.) and 
with cimetidine and one with P.C. and placebo developped stress 
ulcerations, care was not taken to exclude the subgroup fi'om the 
whole sample. (For further conditions ee Methods (section 2.3), 
incidence in % (95% (two-sided) or 97.5% (one-sided) confidence 
intervals) 
Patients Lesions 
Indication Number Number Incidence 
(nl) (n2) (nz/n0 [%] 
Single trauma I05 0 0.0 
(0-3.45) 
Polytrauma 93 2 2.2 
Severe polytrauma, 14 5 35.7 
without prophylaxis (12.76-64.86) 
Severe polytrauma, 14 0 0.0 
with prophylaxis 
Severe polytrauma, 6 0 0.0 
escape 
Trauma total 232 7 3.0 
Abdomen, acute and 410 3 0.7 
unknown of origin 
Postoperative 83 5 6.0 
complications (1.98 13.5) 
Patients at risk 111 3 2.7 
Major surgery 70 0 0.0 
(0-5.13) 
Neurosur85cal operations 39 0 0.0 
(0 9.03) 
Respiratory and cardiac 27 2 7.4 
insufficiency 
Severe infections 16 0 0.0 
Other sporadic indications 92 0 0.0 
Other indications total 848 13 1.5 
Intensive care unit total 1,080 20 1.9 
Table 7. Lethality of all traumatized patients of more then 13 years age admitted to hospital. For 
conditions ee Table 5 and text in Methods (2.3). Without prophylaxis=no cimetidine 
Patients Lethality 
Ward Indication Number Number Incidence 
(nl) (n,) (n2/nl) [%1 
Intensive 
care unit 
Single trauma 105 12 11.4 
Polytrauma 93 16 17.2 
Severe polytrauma, without prophylaxis 14 6 42.9 
Severe potytrauma, with prophylaxis 14 7 50.0 
Severe polytrauma, escape 6 5 83.3 
Trauma total 232 46 19.8 
Casualty Single trauma 701 8 1.1 
Polytranma 124 4 3.2 
Trauma total 825 12 1.5 
Total Trauma total 1,057 58 5.5 
(patients more than 13 years) 
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tion for severe polytrauma: adaptation and cross-adaptation 
against acute ulcerations by lower stressor activities [88] and a 
dose-response relationship between incidence of acute ulcerations 
and severity of each of the pathological states in Table 1 [4, 54, 
87] above a distinct hreshold of stressor activity. Our definition 
is compiled in Table 2. Other definitions [4, 11, 98] had also been 
discussed, but in our opinion suffered from different classes not 
excluding each other satisfactorily [49]. 
Fractures of the spinal column were classed with the corre- 
sponding body cavities (vertebral region of neck with head, thoracic 
region with thorax, lumbar and sacral region and pelvis with abdo- 
men). Lesions of retroperitoneal organs and the bladder also were 
classed with abdominal cavity, The criteria for severe polytrauma 
were assessed by routine clinical investigations, X-rays and findings 
at urgent operations. They could be obtained without relevant 
delay to admit the patients to trial in time (see escape clause). 
Escape and Drop-Out Clause (Table 3 and 4). Patients dying before 
the end of treatment were not considered as drop-outs. On the 
contrary, survival or death were criteria for success or failure of 
ueatment. Furthermore patients developing renal or liver insuffi- 
ciency or leucopenia during treatment could not be excluded auto- 
matically (Table 3 and 4) since these had also to be considered 
as complications of the underlying diseases. 
Patients in escape or drop-out should have standard treatment 
(in our clinic no antacids, cf. [12]. They should or should not 
receive cimetidine according to their consultants opinion (for ethi- 
cal consequences from assuming the null hypothesis in surgical 
trials see [681. 
Groups Treated by Cimetidine and Regimen of Drug Administration. 
Except he cimetidine group with severe polytrauma the drug was 
given for prophylaxis to 1 child in escape (Table 5), t patient 
with severe cerebral injury and t4 patients with respiratory insuffi- 
ciency (all in dropped-out subgroups). For therapy it was applied 
to all patients with stress ulcers in our clinic during the trial period 
including those receiving placebo for prophylaxis. Other patients 
at risk in our hospital certainly did not receive the drug since 
cimetidine was not on the market in Germany till a large period 
of the trial already passed away and candidates for drug delive W 
were controlled in our gastroenterological unit [91]. 
The first day after admission was defined as the first day 
of treatment. Patients coming from midnight ill 4 p.m. (end of 
day duty) received the drug at the same day, those arriving after 
4 p.m. till midnight received the drug at 8 a.m. the next morning. 
Considering the time interval between accident and hospital admis- 
sion see subgroup 2 in Table 3 (escape). Cimetidine was applied 
for two weeks mainly for two reasons which had been carefulIy 
checked: (1) About 90 per cent of acute gastroduodenal lesions 
become clinically manifest in the first two weeks after onset of 
the pathotogicaI states in Table 1 [11, 20, 70, 77, 92]. (2) Severely 
ill patients usuatly stay at least two weeks in our hospital and 
so remain under our surveillance. 
The patients received 1.2 g/day i.v. for 5 days and thereafter 
p.o. for 9 days if their physical state was appropriate. Otherwise 
the drug was continuously applied i.v. tilt the end of treatment. 
The single i.v. dose of 200 mg (about 3 mg/kg) was given in 
4-h intervals by a 2 rain injection or infusion [69] starting at 8 
a.m. The oral dose was applied as 200 mg tablets at meals under 
surveillance of the nurses, 2 tablets at breakfast, 1 at lunch and 
dinner and 2 at bedtime. In renal failure (creatinium ore than 
2.5 mg/dl corresp, to 221 nmol/1) the dose was reduced to 2 x 200 
rag/day (8 a.m. and 8 p.m.) which kept the blood level as high 
as 1.2 g/day in normal conditions [16]. The usual dose and route 
of application were chosen considering both efficacy [1, 76] and 
pharmacokinetics [39]. 
The drug supply for an individual patient was packed as a 
set sufficient for two weeks i.v. plus 9 day p.o. treatment. Both 
drug and placebo were labelled as "Cimetex'. They were admin- 
istered by the nurses and technicians of the ICU who did not 
know whether the patient received verum or placebo. This ~' double- 
blind" design was necessary because the technical staff had first 
to announce visible bleeding in cases of stress ulceration (see be- 
low), 
Clinically Manifest Acute Gastroduodenal U ceration. Their defini- 
tion as acute lesions in the gastroduodenal wall which led to visible 
bleeding and/or perforation was followed by a rather complicated 
procedure of assessment: 
(1) "Clinical manifest ": in all the critically ill patients elected 
for trial routinely a nasogastric tube was inserted for continuous 
suction at least for one week. Manifest Needing was detected either 
by finding visible blood in the gastric aspirate or by recording 
haematemesis and/or metaena following careful observation of the 
patients. To detect blood in the aspirate the nurses and technicians 
additionally were trained and programmed to irrigate the tube 
in the morning and afternoon. If they detected coffe-ground like 
haematin or fresh red blood in the aspirate or recorded haemate- 
mesis and melaena the clinical surgeon of the executive group 
in duty was called who personally tested the gastric content or 
stools and repeated the irrigation. Bleeding was accepted if at 
least in one of the aspirates blood material could undoubtedly 
be seen by him. All other clinical signs of acute ulcerations such 
as fall in blood haemoglobin content, shock or acute abdomen 
were also definitely assessed only by the clinicians of the executive 
committee. 
All 6,634 patients hospitalized for reasons other than already 
manifest acute ulceration were carefully observed for clinical signs 
of upper gastrointestinal bleeding by the staff of the clinic (see 
previous ection). Since, however, continuous uction of gastric 
contents was not performed in most of them the cIinical sign of 
visible blood in gastric aspirate could not be recorded regularly 
in this group of patients. The definite assessment of alt the other 
clinical signs again had to be performed by the clinicians of the 
executive group. 
(2) "Acute ulceration": within the next hour after detecting 
the clinical symptoms of bleeding or perforation urgent endoscopy 
using a transportable endoscopy unit [105] or X-rays for showing 
free air in the abdomen were performed in all cases. If lesions 
were detected they were characterized by assessing their type [90], 
number, bleeding activity [34], localization and expansion. A pho- 
tograph was taken via the endoscope. In some cases the lesions 
were confirmed by surgery. 
They were differentiated from lesions caused by the nasogastric 
tube which showed a typical localization and/or a typical shape 
(e.g. lengthy at the cardia). A series of biopsies was taken for 
microscopical examination to show that the lesions observed were 
acute. All data for the assessment of acute ulceration were recorded 
by a protocol developed for computer-aided diagnosis as part of 
the Airdale Multicentre Study on upper gastrointestinal bleeding 
[1]. For calculating the risk rates for stress ulceration in several 
groups the total number of patients admitted to hospital was ob- 
tained from the admission year books of the clinic administration. 
Final Outcome. Death in patients with severe polytrauma, but also 
in those hospitalized during the trial period was defined in clinical, 
but not in pathoanatomical terms [51] since consent of the relatives 
to perform an autopsy could not be expected in most of the pa- 
tients. Survival was tested tiI discharge from the surgical clinic 
or from any other university hospital if the patients at any time 
after the two weeks treatment in our ctinic had to be transfered 
to them owing to a direct consequence of their accident. This 
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occurred in one patient 16 days after the accident for a delayed 
operation at the E.N.T. clinic. Hospital death was assessed by 
controlling the year-books of the intensive care unit, the wards 
of our clinic and the history of the few others transferred to other 
hospitals by two members of the executive group (M.F. and W.L.) 
independent of another. Special care was taken that the same sub- 
jects were not counted twice because of fluctuations between the 
intensive care unit and the other wards. 
Pathological States and Stressful Conditions (Table 1). The opti- 
mum efficiency for predicting these states by ROC curves [72, 
73] has never been calculated and very probably is also different 
for diagnosing their onset and their duration. Thus relatively simple 
definitions were chosen to acchieve more diagnostic specificity than 
sensitivity [36, 49, 72]. 
(1) Cerebral injury was assessed by case history, clinical 
methods including the Glasgow scale [103], X-ray examinations 
including the skull, angiography and occasionally EEG. (2) Hae- 
morrhagic shock was assessed by clinical methods, physical and 
clinical-chemical measurements and was defined according to 
Allg6wer [2]. Furthermore an arbitrary value of blood-loss was 
given by recording the number of necessary blood transfusions. 
(3) Respiratory insufficiency was differentiated into primary and 
secondary respiratory insufficiency. The first one was defined as 
already existing at hospital admission, the second one as starting 
after at least a 3 day interval of normal respiration (no intubation, 
no artificial respiration ecessary) which followed hospital admis- 
sion or a period of primary respiratory insufficiency. The complica- 
tion was assessed by clinical findings, measurement of blood gases 
and X-rays and was defined according to [7] insisting on the repeat- 
edly obtained evidence ofa p O2 < 60 mm Hg when breathing room 
air. (4) Fat embolism was assessed by case history, clinical findings, 
clinical chemical tests (mainly blood gases) and X-ray examination. 
It was, however, especially difficult o define because of the many 
unspecific symptoms interfering with those of other complications 
in polytraumatized patients [104]. Thus we followed the definition 
of Gurd [40] insisting on the evidence of petechial rash, respiratory 
symptoms plus bilateraI signs with positive radiographic changes. 
(5) Renal insufficiency was assessed by measuring the volume of 
urine/h and by clinical chemical tests including repeated etermina- 
tion of the creatinium concentration i  serum. Especially the last 
mentioned parameter was used for the decision to reduce the daily 
cimetidine dose (see before). Acute renal failure was defined by 
a urine/plasma urea ratio of less than 10 and a urine volume 
of less than 30 mt/h. (6) SepticaI complications were assessed by 
clinical findings, elevated body temperature, performing serial 
blood cultures and recording the effects of antibiotics. They were 
defined according to LeGall et al. [58] by positive blood cultures 
and diagnosis of the initial septic focus. (7) Immobilization was 
registered if a wire extension was performed or if the gypsum 
cast covered at least wo of the extremities. Finally, the application 
of "'ulcerogenic '" drugs was documented both in the trial protocol 
plus in the case history of each of the patients. 
Standard Program of Clinical-Chemical Tests for Studying New 
Drugs [21]. This was performed on day 1, 5 and 14 of the trial, 
paralM to assays of the plasma histamine levels. The time intervals 
were chosen since at the first day elevated plasma histamine l vels 
were expected as a consequence of trauma, shock, operations, infu- 
sions etc. [61, 62]. The highest incidence of clinically manifest 
ulcerations was usually observed around the fifth day after the 
accident and the histamine l vel at the fourteenth day was consid- 
ered as a reasonable control value which could be obtained without 
too many difficulties. Since only very small alterations of the 
plasnaa histamine concentrations were expected to be measured 
[61, 62], a more sensitive assay than at present available [60] had 
to be developed. There are only preliminary reports on this assay 
till now [66, 67], but it will be published in all details in this 
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Fig. 1. RST plan for the sequential c inical trial comparing cimeti- 
dine and placebo for prophylaxis of stress ulceration in patients 
with severe polytrauma. Two-sided overall significance level 2~,= 
0.05, power 1-/?=0.95, critical value 0=0.95 [3]. The bold line 
shows the progress in trial, It was stopped before the upper boun- 
dery was reached. For explanation see text in Statistics. U = upper 
boundery, L=lower boundery, M"=modified middle boundery 
[3] 
series of communications. Furthelnnore it was considered essential 
to take blood samples always at the same time of the day (7.30--8.00 
a.m.) and because of histamine release always before the first 
cimetidme application on that particular day [69]. 
4. Statistics 
Generally the 95% confidence intervals (two-sided) were estimated 
for the incidences of stress ulceration in several groups of patients 
in our Surgery Clinic [49]. Only in cases where the incidence was 
zero the 97.5% confidence interval (one sided) was calculated (P~ = 
l-antilog (loge/N)) [36a]. Regarding these values and with respect 
to the prospective sampling of our data some comparative rates 
("risk rates") were calculated for reasonable large sample sizes 
according to Cornfield (17 a) (see also [50]). Enforced by our ethical 
committee for significance testing an appropriate RST plan [3] 
was constructed for sequential experimentation (Fig. 1). Random- 
ization was performed in blocks of 4 patients [3]. it was assumed 
from literature (Table I) and from our data in the prospective 
study [92] that in severe polytrauma the incidence of stress ulcer- 
ations would be about 30 per cent using placebo (~rl). If cimetidine 
was expected to be highly effective (see introduction) in a sample 
af about 50 patients the smallest incidence of stress ulceration 
would be reasonably predicted as about 2 per cent (~2). Choosing 
a critical value 0=0.95, an overall significance level (2~)=0.05 
and a power (I-]~)=0.95 the number of preferences in the RST 
plan would be maximum 10 corresponding to maximum 66 patients 
if qb would be 0.31. The average sampIe number (ASN) in these 
conditions would be 6.8 preferences corresponding to 44 patients 
[3]. Since the stopping rule based on repeated two-sided significance 
tests, a nominal significance level 2 f  less than 0.05 had to be 
chosen and was 0.0313 in our plan (Fig. 1). 
After stopping the trial for ethical reasons the exact test of 
Fisher [32] was used for testing significance in the sample of patients 
with severe polytrauma. 
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Results 
1. Incidence of Stress Ulcerations in the Patients 
of the Marburg Surgery Clinic 
The Surgery Clinic in Marburg with 170 beds is situ- 
ated in a city of 60,000 inhabitants urrounded by 
rural areas in North Hessia. It has the function of 
a district hospital since in a circumference of about 
40 km no other surgery clinic of a reasonable size 
and of appropriate medical facilities can be found. 
These conditions are very favourable for drawing con- 
clusions from findings in our trial sample to those 
on the corresponding target population. 
However, some other factors which are less com- 
mon may have influences on our clinic population. 
For instance we have an excellent cooperation with 
the Medical Clinic including common seminars for 
treatment of difficult cases. Thus it cannot be excluded 
that especially in abdominal diseases as the main in- 
terest of the two units some of the incidences for 
stress ulceration are biased by hospital admission [8]. 
Also the introduction of highly qualified neurosurgery 
from Giessen into our clinic in Marburg may have 
positively influenced the results. Finally during social 
analysis of our sample we become aware of the fact 
that North Hessia contains a higher proportion of 
refugees and foreign workers than other federal 
countries. 
Taking into account these pecularities nevertheless 
we drew some cautious conclusions. The overall inci- 
dence of clinically manifest stress ulcerations in pa- 
tients hospitalized in the Surgery Clinic was 0.3% 
(Table 5). This was about 5-times lower than the 
incidence of ileus or the prevalence of chronic duo- 
denal ulcer in our hospital population [92] and may 
therefore be considered as rather low. 
The occurrence of acute upper gastrointestinal le-
sions, however, was not uniformly distributed over 
the various wards and units. Using the confidence 
interval s (see section Statistics) the incidence of stress 
ulceration was 1.9 (1.16-2.82)% in the intensive care 
unit, but 0 (0-0.07)% in all other parts of the hospital 
(Table 5). This significant and important difference 
enforced us to look for further specification of the 
groups at risk for stress ulceration. 
2. Incidence of Stress Ulcerations in Various Groups 
of Patients in the Intensive Care Unit 
in the casualty ward and intensive care unit (Table 
5 and 6), the incidence of stress ulceration was fairly 
low (0.98 (0.12-3.51)%), but extremely high in the 
patients with severe polytrauma s defined in this 
study (35.7 (12.76-64.86)%). The risk rate was calcu- 
lated [17a] to be 35-times higher in patients with sev- 
ere polytrauma than in those with (only) polytrauma 
which clearly destined this group for trial in stress 
ulcer prophylaxis. However, in single trauma and also 
largely in polytrauma ny kind of special stress ulcer 
prophylaxis (antacids, somatostatin, secretin, vago- 
lytic drugs or H2-receptor antagonists) eems unneces- 
sary which strongly contradicts common practice in 
this country. 
In non-trauma patients in the intensive care unit 
(Table 6) rather surprising results were obtained if 
the reports in the literature (Table 1) were compared 
to them. Major surgery (0(0-5.13) %) and neurosurgi- 
cal operations (0(0-9.03)%) were not afflicted with 
a high risk of stress ulceration whereas postoperative 
complications (anastomotic insufficiency, peritonitis 
etc.) were associated such with a remarkable incidence 
of acute lesions as 6 (1.98-13.5)%. The series of pa- 
tients investigated in this prospective trial clearly is 
not large enough to permit a reliable calculation of 
all the comparative rates for stress ulceration which 
would be interesting for the clinicians. Since, however, 
for instance major surgery per se did not increase 
the risk of upper gastrointestinal bleeding, but only 
in combination with postoperative complications, 
these data already demand a new and more appropri- 
ate definition and classification of patients at risk 
for stress ulceration. Only by this a specific prophy- 
laxis can be inaugurated instead of distributing any 
drug with all its side-effects over the intensive care 
unit for treatment of so critically ill patients. 
3. Death Rates in Various Groups of Trauma Patients 
To facilitate some conclusions from the sample of 
our patients to the target population of patients ad- 
mitted to centres with accidental surgery the death 
rates were considered as especially useful (Table 7) 
because of their relationship to the severity of the 
diseases. In this respect it was quite remarkable how 
much the death rates were in agreement with those 
of other centres in Germany which are particularly 
specialized for accident surgery [27, 99]. 
Also in the intensive care unit the risk for stress ulcer- 
ation was not uniformly distributed (Table 5 and 6). 
In single trauma, even complicated by fat embo- 
lism, no bleeding occurred in the trial period (inci- 
dence 0 (0 3.45)). In patients with polytrauma, both 
4. Comparison of Attributes in Patients 
with Severe Polytrauma 
Concerning all the pathological states and stressful 
conditions (Table 1) the cimetidine group of patients 
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with severe polytrauma was in excellent agreement 
to the placebo group. Only the number of immediate 
operations was 9 in the cimetidine group, but only 
5 in the placebo group. All other details of these 
two subgroups will be published in the second com- 
munication [3 I]. 
Discussion 
A meticulous description of methodological details 
is critical for an article both with respect o readers 
and authors. Much time is necessary to find the way 
through all the pages, and the large size probably 
will deter many people from coming to terms with 
this communication. A sophisticated and (possibly) 
competitive scientist will find so many branchings 
of the decision tree that he is rather urged to prepare 
a list of all those occasions where h  would like to 
elect just that condition which has been rejected in 
the design of this trial. If any detail, however, is 
missed by the reader he may suspect with more justifi- 
cation that it has been overlooked in conducting the 
trial than in the many articles today which enumerate 
"facts" and torment he fantasy of critical readers 
with assumptions how probably the findings were ob- 
tained, 
Nevertheless we have chosen this risk for several 
reasons: 
(1) in clinical science data usually are not as repro- 
ducible as in enzymology or analytical chemistry since 
conditional and interfering factors as well as all their 
combinations are extremely more numerous in clinical 
trials than in laboratory experiments. But how should 
readers and authors have even the slightest chance 
of a possibility to explain agreements or (usually more 
often) disagreements of results obtained from clinical 
trials if we do not describe or define as skilfully as 
possible all those conditions in our study which 
at any time came to our mind? This article is an 
attempt o reconcile the flagrant contradiction that 
in thousands of clinical studies and dozens of random- 
ized controlled trials where much more conditions 
have to be considered than in experiments in vitro 
less scruting in description is observed than in any 
article published in Journal of Biological Chemistry. 
(2) Basic research scientists including several sta- 
tisticians have recommended very strict and rather 
idealized rule for clinical research. Others have warn- 
ed the community that controlled clinical trials are 
too difficult to execute. Clinical researchers, however, 
especially in the field of gastroenterology have 
produced the impression by publishing numerous pa- 
pers on controlled clinical trials that it is relatively 
easy to conduct such studies. In our opinion none 
of these "experiences" is adequate to the problem. 
Again the report on our trial should be an attempt 
to emphasize that controlled clinical trials can be 
superior to other "designs" of clinical research, but 
should never be expected to be perfect. They are labo- 
rious, time-consuming and like the life itself-  never 
completely calculable, especially with respect o fu- 
ture, but they are not too difficult to conduct. In 
our opinion many "well-done" controlled random- 
ized double-blind trials with their superficial presenta- 
tion have harmed this very valuable idea and have 
created many of the ethical controverses which in 
this country arose in the last few years [14@ 
As a special point the deviations from the usual 
structure of an original communication should be dis- 
cussed. To elucidate the background of the design 
of a rather complex clinical trial an introduction was 
considered to be too short and not informative 
enough. Thus a section of °' theoretical aspects" was 
introduced. The historical aspects of the study were 
put into a separate section since it was important 
both for the design and the execution of the project. 
From a statistical point of view it is by no means 
justified to assume that a drop-out of subgroups or 
change in the medical staff (neurosurgeon) had no 
consequences for the outcome of the trial. We know 
that it is common use to conceal such changes in 
the conditions of a "clinical experiment", but in our 
experience and in our knowledge about "successful" 
clinical trials around the world it happens so often 
...... and why should its influence on the data in trials 
not carefully be investigated and confessed. It is in 
the hands of conductors of clinical trials themselves 
to convince or make ashamed their critics by their 
courage for truth and modesty. Finally in the design 
of the trial there were so many decisions which by 
other investigators would have been made just into 
the opposite direction. The article would have been 
cut to not yet readable pieces of all the decisions 
would have been explained so much later on in a sepa- 
rate section of the discussion. It was our purpose 
to perform an experiment on controlled clinical trials 
- i f  it stimulates the discussion then it has hit the 
mark. 
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